ArticleMediastinum (Hong Kong, China)2025
Clinico-pathologic study of 252 resected thymomas with emphasis on atypical A and AB group: a single institution experience.
Article in Mediastinum (Hong Kong, China), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: World Health Organization (WHO) classification defines subdivision of type B group (B1, B2, and B3) based on proportion of neoplastic epithelial cells and non-neoplastic lymphocytes, and a number of studies have demonstrated correlation between the subtype and prognosis, with type B3 being unfavorable. Type A and AB tumors share similar clinico-pathological features, with generally indolent behavior, and both are characterized by GTF2I mutation. A subset of type A and AB tumors shows atypical features such as increased mitotic activity, cytologic atypia and necrosis, and the term atypical type A has been proposed; however, the atypical category is not well-defined. Aim of the study is to establish criteria for atypical type A thymoma. Methods: A total of 252 thymomas resected from 247 patients were retrieved and reviewed. A variety of clinical and histopathologic parameters were recorded and analyzed, and prognostic factors in type A and AB group were investigated in order to better define the atypical category. Results: Median age was 63 years (range, 14-84 years), equal male:female ratio (121:129), median tumor size 65 mm (range, 10-300 mm). There were 46 tumors (type A), 105 (AB), 22 (B1), 47 (B2), and 32 (B3). The majority of patients with A/AB subtypes were above 63 years old, whereas the majority of patients with B group were below 63 years old. Type B group was more often of advanced stage compared to A/AB. Vascular invasion was shown more often in subtype A and necrosis in subtype B1. AB group included larger tumors than the other subtypes. Paraneoplastic syndromes were reported in 71 (28.4%) patients and were more frequently seen in subtypes B2 and B3. In A/AB group, multivariate Cox proportional hazard models demonstrated that mitotic count was the only independent prognostic factor as continuous variable [hazard ratio (HR) 1.15, 95% confidence interval (CI): 1.07-1.24, P<0.001]. A/AB cases were further classified by mitotic count in 4 groups (1-4, 5-9, 10-19 and ≥20 mitotic figures per 2 mm Conclusions: Our results suggest atypical type A and AB could be defined as tumors with ≥20 mitotic figures per 2 mm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.